ALTB-168
Acute Graft vs. Host Disease
Phase IActive
Key Facts
About AltruBio
AltruBio is a private, clinical-stage biotech focused on novel biologics that modulate T-cell activity via the PSGL-1 checkpoint. The company's pipeline is anchored by ALTB-268, a next-generation candidate for ulcerative colitis now in Phase 2a, with plans for indication expansion. Having recently secured a significant $225M Series B financing, AltruBio has strengthened its financial position to advance its clinical programs. The company operates with a dual headquarters in San Francisco and a key R&D center in Taipei, Taiwan.
View full company profile